转化癌症研究 SCIE

期刊简介预计审稿时间：

Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.

转化癌症研究 (Transl Cancer Res TCR；印刷 ISSN：2218-676X；在线 ISSN 2219-6803；http://tcr.amegroups.com/) 是一本开放获取、同行评审的期刊，收录于科学引文索引扩展版 (SCIE)。TCR 发表新型治疗干预的实验室研究以及评估癌症新治疗模式的临床试验；新型研究调查的结果，这些调查将实验室和临床环境连接起来，包括风险评估、细胞和分子表征、人类癌症的预防、检测、诊断和治疗，总体目标是改善癌症患者的临床护理。TCR 的重点是原创的、同行评审的、基于科学的研究，这些研究成功地推动了临床医学朝着改善患者生活质量的目标发展。编辑和由科学家、临床科学家以及其他专家组成的国际顾问团将确保 TCR 文章达到高质量标准。我们接受原创文章以及评论文章、社论和简短文章。

《Translational Cancer Research》(转化癌症研究)编辑部通讯方式为FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, PEOPLES R CHINA, HONG KONG, 00000。如果您需要协助投稿或润稿服务，您可以咨询我们的客服老师。我们专注于期刊投稿服务十年，熟悉发表政策，可为您提供一对一投稿指导，避免您在投稿时频繁碰壁，节省您的宝贵时间，有效提升发表机率，确保SCI检索（检索不了全额退款）。我们视信誉为生命，多方面确保文章安全保密，在任何情况下都不会泄露您的个人信息或稿件内容。